SHH:688278
Xiamen Amoytop Biotech Co., Ltd. · SHH · Healthcare · CNY · FY for 2025
Figures on this page computed 2026-11-07 23:39 UTC
Last close
n/aCNY
Market data
We are not showing closes for this listing. A line drawn through points we do not hold would look exactly like a listing that did not move.
17.8xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
- Computed from the filing for 2025
35.4%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
27.9%Net margin
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
12.8%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
0.05Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
6 of 6 traits placed on the market's range. Nothing sits below its sector's middle.
Five bars, one line
lens 7 of 9Each against its own average
4 of 5 readExcept where said otherwise: Computed from the filing for 2025
- Sales2.67x
Its own average over 10 years, 1.38B.
- Profit3.31x
Its own average over 10 years, 311.4M.
- Free cash flow4.27x
Its own average over 10 years, 110.8M.
- Debt3.26x
Its own average over 10 years, 53.9M.
- Pricen/a
Its own average over 0 years. Market data
Free cash flow is furthest from its own average, at 4.27 times.
The filed years, as a table
10Each line is 100 at 2016-12-31, the first year we hold.
| Filed year | Sales | Profit | Shares in issue |
|---|---|---|---|
| 2016-12-31 | 100.0 | 100.0 | 100.0 |
| 2017-12-31 | 115.2 | 17.6 | 158.7 |
| 2018-12-31 | 159.9 | 54.6 | 122.8 |
| 2019-12-31 | 260.3 | 219.3 | 109.7 |
| 2020-12-31 | 283.2 | 397.7 | 123.4 |
| 2021-12-31 | 403.8 | 618.1 | 123.6 |
| 2022-12-31 | 544.6 | 979.1 | 124.1 |
| 2023-12-31 | 749.1 | 1,894.8 | 124.5 |
| 2024-12-31 | 1,004.8 | 2,823.2 | 125.2 |
| 2025-12-31 | 1,318.1 | 3,517.9 | 124.9 |
How sales was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
How profit was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
How shares in issue was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
Figures behind the shape
Growth
36.0%faster is higher, placed against 4,950 companies as of 2026-11-06
Five-year revenue growth rate36.0%
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
Five-year EPS growth rate54.2%
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
One-year change in net income24.6%
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
Returns on capital
35.4%higher is higher, placed against 5,089 companies as of 2026-11-06
Return on invested capital35.4%
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Return on equity29.9%
Net Income / Shareholders' Equity x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Return on assets23.4%
Net Income / Total Assets x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Margins
93.0%wider is higher, placed against 3,412 companies as of 2026-11-06
Gross margin93.0%
Gross Profit / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Operating margin33.5%
Operating Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Net margin27.9%
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Free cash flow margin12.8%
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Price
17.8xcheaper is higher, placed against 4,362 companies as of 2026-11-06
Price to earnings17.8x
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
- Computed from the filing for 2025
Price to book5.3x
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
- Computed from the filing for 2025
- computed
- Computed from the filing for 2025
EV to EBITDA13.6x
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Price to sales ratio5.0x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
- Computed from the filing for 2025
- Computed from the filing for 2025
Safety
0.05safer is higher, placed against 3,227 companies as of 2026-11-06
Debt to equity0.05
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Current ratio3.86
Current Assets / Current Liabilities
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Interest coverage870.0x
Operating Income / Interest Expense
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Altman Z-Score14.96
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
What it pays out
24.5%more, and better covered, is higher, placed against 1,091 companies as of 2026-11-06
Dividend yieldn/a
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
Payout ratio24.5%
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Dividend cover ratio1.9x
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
Share a finding
A link to the finding, not to you: it carries nothing about your account.